Jennison Associates LLC Verve Therapeutics, Inc. Transaction History

Jennison Associates LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$20.92 - $39.36 $9.39 Million - $17.7 Million	-448,765 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$31.94 - $54.82 $2.66 Million - $4.56 Million	83,188 Added 22.76%	448,765 $16.5 Million
Q3 2021 Nov 09, 2021	SELL	$46.0 - $73.99 $203,458 - $327,257	-4,423 Reduced 1.2%	365,577 $17.2 Million
Q2 2021 Aug 12, 2021	BUY	$31.92 - $60.25 $11.8 Million - $22.3 Million	370,000 New	370,000 $22.3 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $291M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.